Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
Infection ; 2024 May 03.
Article in English | MEDLINE | ID: mdl-38700656

ABSTRACT

PURPOSE: The influence of new SARS-CoV-2 variants on the post-COVID-19 condition (PCC) remains unanswered. Therefore, we examined the prevalence and predictors of PCC-related symptoms in patients infected with the SARS-CoV-2 variants delta or omicron. METHODS: We compared prevalences and risk factors of acute and PCC-related symptoms three months after primary infection (3MFU) between delta- and omicron-infected patients from the Cross-Sectoral Platform of the German National Pandemic Cohort Network. Health-related quality of life (HrQoL) was determined by the EQ-5D-5L index score and trend groups were calculated to describe changes of HrQoL between different time points. RESULTS: We considered 758 patients for our analysis (delta: n = 341; omicron: n = 417). Compared with omicron patients, delta patients had a similar prevalence of PCC at the 3MFU (p = 0.354), whereby fatigue occurred most frequently (n = 256, 34%). HrQoL was comparable between the groups with the lowest EQ-5D-5L index score (0.75, 95% CI 0.73-0.78) at disease onset. While most patients (69%, n = 348) never showed a declined HrQoL, it deteriorated substantially in 37 patients (7%) from the acute phase to the 3MFU of which 27 were infected with omicron. CONCLUSION: With quality-controlled data from a multicenter cohort, we showed that PCC is an equally common challenge for patients infected with the SARS-CoV-2 variants delta and omicron at least for the German population. Developing the EQ-5D-5L index score trend groups showed that over two thirds of patients did not experience any restrictions in their HrQoL due to or after the SARS-CoV-2 infection at the 3MFU. CLINICAL TRAIL REGISTRATION: The cohort is registered at ClinicalTrials.gov since February 24, 2021 (Identifier: NCT04768998).

3.
Sci Rep ; 12(1): 3613, 2022 03 07.
Article in English | MEDLINE | ID: mdl-35256685

ABSTRACT

Improving sleep quality in patients with obstructive sleep apnea (OSA) by positive airway pressure therapy is associated with a decrease of blood pressure (BP). It remains elusive, whether treatment of sleep disturbances due to restless legs syndrome with symptomatic periodic limb movements in sleep (PLMS) affects BP as well. The present study provides first data on this issue. Retrospective study on patients undergoing polysomnography in a German University Hospital. Inclusion criteria were first diagnosis of restless legs syndrome with PLMS (PLM index ≥ 15/h and PLM arousal index ≥ 5/h) with subsequent initiation of levodopa/benserazide or dopamine agonists. Exclusion criterion was an initiation or change of preexisting positive airway pressure therapy between baseline and follow-up. BP and Epworth sleepiness scale were assessed at two consecutive polysomnographies. After screening of 953 PLMS data sets, 114 patients (mean age 62.1 ± 12.1 years) were included. 100 patients (87.7%) were started on levodopa/benserazide, 14 patients (12.2%) on dopamine agonists. Treatment was associated with significant reductions of PLM index (81.2 ± 65.0 vs. 39.8 ± 51.2, p < 0.001) and ESS (6 [interquartile range, IQR, 3-10.5] vs. 5 [IQR 3-10], p = 0.013). Systolic BP decreased from 132.9 ± 17.1 to 128.0 ± 15.8 mmHg (p = 0.006), whereas there was no significant change of diastolic BP (76.7 ± 10.9 vs. 75.1 ± 9.2 mmHg, p = 0.15) and heart rate (71.5 ± 11.9 vs. 71.3 ± 12.7, p = 0.84). The number of antihypertensive drugs remained unchanged with a median of 2 (IQR 1-3, p = 0.27). Dopaminergic treatment of PLMS is associated with an improvement of sleep quality and a decrease of systolic BP comparable to treatment OSA.


Subject(s)
Restless Legs Syndrome , Sleep Apnea Syndromes , Sleep Apnea, Obstructive , Aged , Benserazide/therapeutic use , Blood Pressure , Dopamine Agonists , Humans , Levodopa/therapeutic use , Middle Aged , Retrospective Studies , Sleep , Sleep Apnea Syndromes/complications , Sleep Apnea, Obstructive/complications , Sleep Apnea, Obstructive/drug therapy
4.
MMW Fortschr Med ; 163(5): 28, 2021 03.
Article in German | MEDLINE | ID: mdl-33710551
5.
Dtsch Med Wochenschr ; 144(21): 1522-1527, 2019 10.
Article in German | MEDLINE | ID: mdl-31634930

ABSTRACT

Arterial hypertension is one of the most prevalent chronic diseases, and a major risk factor for cardiovascular diseases. It is essential to perform the blood pressure measurement under standardized conditions in the office/clinical setting, otherwise inaccuracy of blood pressure values may lead to poor blood pressure control or misdiagnosis. Compliance with these standards by a trained observer is of crucial importance for a reliable and accurate blood pressure measurement in clinical practice. Regardless of the standardized assessment, it has to be kept in mind that available devices on the market may not measure blood pressure accurate enough. Therefore, a validated (e. g. German Hypertension League Quality Seal) blood pressure monitor should be used. Out-of-office (home and ambulatory) blood pressure measurements provide important information beyond determining resting office/clinical BP.


Subject(s)
Blood Pressure Determination/methods , Blood Pressure Determination/standards , Blood Pressure/physiology , Hypertension/diagnosis , Germany , Humans
6.
Hepatogastroenterology ; 59(120): 2508-11, 2012.
Article in English | MEDLINE | ID: mdl-22497952

ABSTRACT

BACKGROUND/AIMS: To evaluate the usefulness of pre-endoscopic assessment for predicting active up-per gastrointestinal bleeding (UGI-B) at emergency esophagogastroduodenoscopy (E-EGD, within 6 hours). METHODOLOGY: We retrospectively analysed the medical records of patients that had an E-EGD performed outside working hours and considered 15 pre-endoscopic variables in a univariate analysis. Active UGI-Bat E-EGD was taken as end-point. RESULTS: Of 228 E-EGD performed during 75 months, 195 were motivated by the suspicion of UGI-B. We excluded 83 cases as they were hospitalised at the time of first symptoms of bleeding. Thus, 112 cases were included. The following clinical signs triggered E-EGD: hematemesis (56/50%),melena (55/49.1%), hematochezia (20/17.8%), anae- mia (7/6.2%). Patients' age was 65.5+14.2 years. Sixty nine (61.6%) cases were male. The relative risk and p-value of the variables for the presence of active bleeding at E-EGD were as follows: hematemesis: 1.54/0.3; malignancy and cirrhosis: 1.73/0.07; haemoglobin <8g/dL: 1.38/0.3; white blood count >12,000/tL: 1.18/0.6;systolic blood pressure (SBP) <100 mmHg: 0.53/0.03;pulse >100/min: 1.42/0.2; platelets <14000/nL:1.5/0.2; INR >1.17: 1.89/0.049. In the multivariate analysis none of these variables independently predicted UGI-B. CONCLUSIONS: No relevant pre-endoscopic variables for the prediction of active UGI-B at E-EGD could be found. Our data suggest that pre-endoscopic evaluation cannot replace rapid endoscopy.


Subject(s)
After-Hours Care , Endoscopy, Gastrointestinal , Gastrointestinal Hemorrhage/diagnosis , Aged , Anemia/etiology , Emergencies , Female , Gastrointestinal Hemorrhage/etiology , Germany , Hematemesis/etiology , Hospitals, University , Humans , Logistic Models , Male , Melena/etiology , Middle Aged , Multivariate Analysis , Odds Ratio , Predictive Value of Tests , Retrospective Studies , Risk Assessment , Risk Factors , Time Factors
7.
Sleep Breath ; 16(1): 123-33, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21213062

ABSTRACT

PURPOSE: A close relationship between obstructive sleep apnea (OSA) and atherosclerosis has been reported, but it is still discussed controversially whether OSA affects vascular function and structure independently. Therefore, we prospectively investigated the independent impact of OSA and its treatment on arterial stiffness. METHODS: One hundred seventy-two patients with suspected OSA were prospectively enrolled in a non-randomized 6-month study to determine whether effective treatment (respiratory events sufficiently reduced and proven compliance) of OSA with continuous positive airway pressure (CPAP) would affect vascular function as measured by augmentation index (Aix) and pulse wave velocity (PWV). Additionally, using a nested case-control, we matched 45 pairs of patients with and without OSA for gender, age, and hypertension. RESULTS: Overall, OSA (n = 117) was associated with increased Aix (23.6 ± 13.5 vs. 8.9 ± 13.7, p < 0.001) and PWV (9.1 ± 1.6 vs. 7.8 ± 1.6 m/s, p < 0.001) as compared with that in controls without OSA (n = 55). Multivariable analysis and results from the nested case-control cohort showed that OSA was associated with increased Aix and PWV independently from hypertension, age, gender, body mass index, and antihypertensive medications. In 49 effectively treated OSA patients, Aix (baseline 22.0 ± 13.4, follow-up 20.1 ± 12.9, p < 0.01) and PWV (baseline 9.6 ± 1.5, follow-up 8.7 ± 1.4, p < 0.05) had improved. In contrast, ineffectively treated OSA patients (n = 39) showed no change in Aix and PWV. CONCLUSIONS: This prospective controlled study suggests that OSA is independently associated with increased arterial stiffness. Furthermore, treatment with CPAP significantly reduced arterial stiffness. These findings extend our understanding of the recently shown cardiovascular burden in OSA and help to explain why CPAP treatment proved to ameliorate cardiovascular outcome even in patients without preexisting cardiovascular disease.


Subject(s)
Atherosclerosis/physiopathology , Atherosclerosis/therapy , Continuous Positive Airway Pressure , Mandibular Advancement/instrumentation , Occlusal Splints , Sleep Apnea, Obstructive/physiopathology , Sleep Apnea, Obstructive/therapy , Vascular Stiffness/physiology , Adult , Aged , Blood Pressure/physiology , Cohort Studies , Diabetes Mellitus, Type 2/physiopathology , Diabetes Mellitus, Type 2/therapy , Female , Germany , Humans , Hypertension/physiopathology , Hypertension/therapy , Male , Middle Aged , Polysomnography , Prospective Studies , Risk Factors , Treatment Outcome
8.
Respiration ; 82(5): 409-17, 2011.
Article in English | MEDLINE | ID: mdl-21311167

ABSTRACT

BACKGROUND: Endothelial dysfunction has recently been demonstrated in obstructive sleep apnea (OSA), but the underlying mechanisms are not entirely understood. Oxidative stress is a typical feature of OSA. OBJECTIVES: We investigated the influence of oxidative stress and continuous positive airway pressure (CPAP) on microvascular endothelial function in OSA. METHODS: Endothelial function of forearm resistance vessels was assessed by strain gauge venous occlusion plethysmography after intra-arterial infusion of the endothelium-independent vasodilator sodium nitroprusside (1.6, 3.2, and 4.0 µg/min) and the endothelium-dependent vasodilator acetylcholine (Ach, 15, 30 and 40 µg/min) in patients with (n = 11) and without (n = 8) OSA (apnea-hypopnea index ≥15/h). These measurements have been repeated after local intra-arterial infusion of the antioxidant vitamin C (25 µg/min). Furthermore, 6 patients have been reevaluated after 6 months of OSA treatment. RESULTS: Patients with OSA demonstrated impaired endothelial function compared to those without OSA. Thus, related to baseline flow, the increase in forearm blood flow induced by Ach was blunted in patients with OSA (148.7 ± 29.7% in OSA vs. 233.6 ± 45.7% in controls, p = 0.001). This difference, however, was abolished by co-infusion of vitamin C. Endothelial function markedly improved following treatment in 5 of 6 OSA patients. CONCLUSIONS: This study strongly suggests that microvascular endothelial function is affected by OSA predominantly through increased oxidative stress, and treatment of OSA may improve endothelial function mainly by reducing oxidative stress. The role of oxidative stress-induced endothelial dysfunction as a potential promoter of atherosclerosis and an increased cardiovascular risk in patients with OSA should be investigated in further controlled studies.


Subject(s)
Continuous Positive Airway Pressure , Endothelium, Vascular/physiopathology , Oxidative Stress , Sleep Apnea, Obstructive/physiopathology , Vasodilator Agents/therapeutic use , Acetylcholine/administration & dosage , Ascorbic Acid/administration & dosage , Atherosclerosis/physiopathology , Blood Flow Velocity , Capillaries/physiopathology , Female , Forearm/blood supply , Humans , Infusions, Intra-Arterial , Male , Microcirculation , Middle Aged , Nitroprusside/administration & dosage , Plethysmography , Polysomnography , Prospective Studies , Sleep Apnea, Obstructive/complications , Sleep Apnea, Obstructive/therapy , Vascular Resistance
9.
Nephrol Dial Transplant ; 26(3): 914-20, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20682605

ABSTRACT

BACKGROUND: Impaired renal function has recently been reported in obstructive sleep apnoea (OSA). The underlying mechanisms, however, are not entirely understood. This study investigated the influence of mild-to-moderate OSA and its treatment on renal haemodynamics as assessed by the renal resistance index (RRI). METHODS: RRI has been measured by colour duplex ultrasound in 64 patients with newly diagnosed mild-to-moderate OSA and 61 controls without OSA at baseline and follow-up after 9.9 months. Treatment with continuous positive airway pressure was offered to all patients with OSA (apnoea/hypopnoea index ≥ 5/h). RESULTS: Increased values of RRI (≥ 1 SD [8.9%] above the age-adjusted normal value) were found in 41 out of 64 (64.0%) OSA patients when compared with 20 out of 61 (32.8%) controls (P < 0.001). The corresponding mean RRI was 70.50 ± 9.01 vs 66.51 ± 8.33 (P = 0.012). In multivariate analyses, the influence of OSA on RRI was independent from hypertension, diabetes mellitus, age and baseline renal function. At follow-up, RRI decreased only in patients with effective OSA treatment but remained unchanged in ineffectively treated OSA patients and controls. CONCLUSIONS: For the first time, this prospective controlled observational study demonstrates an impairment of renal haemodynamics in OSA as measured by an increased RRI. These changes of renal blood flow may identify OSA patients at high risk of declining renal function. Both parenchymal and vascular renal diseases are proposed as pathomechanisms for this association. An effective treatment of OSA resulted in a decreased RRI, suggesting an improvement in renal perfusion. Further studies are needed to elucidate the role of impaired renal haemodynamics in OSA.


Subject(s)
Continuous Positive Airway Pressure , Renal Artery Obstruction/etiology , Sleep Apnea, Obstructive/complications , Sleep Apnea, Obstructive/prevention & control , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prognosis
10.
J Med Case Rep ; 3: 9216, 2009 Sep 08.
Article in English | MEDLINE | ID: mdl-19918292

ABSTRACT

INTRODUCTION: Pneumatosis cystoides intestinalis is characterized by the presence of multiple gas-filled cysts in the intestinal wall, the submucosa and/or subserosa of the intestine. The term pneumatosis cystoides coli is synonymous with pneumatosis cystoides intestinalis when the disorder is limited to the colon. It is a secondary finding caused by a wide variety of underlying gastrointestinal or extragastrointestinal diseases but rarely occurs in the course of treatment with an alpha-glucosidase inhibitor. This is the first report of pneumatosis cystoides intestinalis after 12 years of treatment with the alpha-glucosidase inhibitor acarbose. CASE PRESENTATION: A 65-year-old Caucasian German woman was referred to our hospital for hemicolectomy. She had been treated for type 2 diabetes mellitus with an alpha-glucosidase inhibitor (acarbose, 150 mg daily) for 12 years. Three months before referral, she had complained of left abdominal pain. 'Polyposis coli' in the ascending colon and diverticulosis were diagnosed. Colonoscopy and computed tomography scans of the abdomen were repeated and revealed pneumatosis cystoides coli located in the ascending colon, whereas diverticulosis of the sigmoid colon was confirmed. Histological examination of a biopsy specimen only showed colon mucosa. After discontinuing administration of the alpha-glucosidase inhibitor for 3 months and on repeated colonoscopy, the polypoid lesions had completely disappeared. CONCLUSION: This case illustrates that pneumatosis cystoides coli can be a source of diagnostic confusion. Pneumatosis cystoides coli must be considered in the initial differential diagnosis of patients especially in the presence of multiple colonic polypoid lesions. It is important to take pneumatosis cystoides intestinalis into consideration when prescribing alpha-glucosidase inhibitors to patients with diabetes who have diabetic autonomic neuropathy with decreased intestinal motility, or to patients taking steroids.

12.
Am J Respir Crit Care Med ; 176(12): 1274-80, 2007 Dec 15.
Article in English | MEDLINE | ID: mdl-17673692

ABSTRACT

RATIONALE: Obstructive sleep apnea (OSA) is linked to increased cardiovascular risk, but the impact of mild forms of OSA and their treatment on cardiovascular outcomes remains controversial. OBJECTIVES: To prospectively investigate cardiovascular outcomes in treated versus untreated patients with OSA. METHODS: Consecutive sleep laboratory patients with all degrees of OSA were included. Endpoints were nonfatal (myocardial infarction, stroke, and acute coronary syndrome requiring revascularization procedures) and fatal (death from myocardial infarction or stroke) cardiovascular events. MEASUREMENTS AND MAIN RESULTS: Comparison of event-free survival rates in treated versus untreated patients (Kaplan-Meier estimates, log-rank test). Of 449 patients enrolled (age, 56.0 +/- 10.5 years; body mass index, 30.8 +/- 5.4 kg/m(2)), 364 patients received OSA treatment, and 85 patients remained untreated. Median follow-up was 72.0 months (range, 1-156). Mean apnea-hypopnea index before treatment was 30.9 +/- 21.8/hour in treated and 15.3 +/- 13.0/hour in untreated patients, but there were no differences in cardiovascular comorbidities or risk factors. In patients with mild-moderate OSA (n = 288), events were more frequent in untreated patients (estimated event-free survival at 10 yr, 51.8 vs. 80.3% [P < 0.001]; absolute risk reduction, 28.5%; number needed to treat to prevent one event/10 yr, 3.5). After adjustment for age, gender, cardiovascular risk factors, and comorbidities at baseline, OSA treatment was an independent predictor for events (hazard ratio, 0.36; 95% confidence interval, 0.21-0.62; P < 0.001). CONCLUSIONS: OSA treatment was associated with a cardiovascular risk reduction of 64% independent from age and preexisting cardiovascular comorbidities. OSA treatment should be considered for primary and secondary cardiovascular prevention, even in milder OSA.


Subject(s)
Cardiovascular Diseases/therapy , Continuous Positive Airway Pressure , Sleep Apnea Syndromes/complications , Sleep Apnea Syndromes/therapy , Adult , Aged , Cardiovascular Diseases/complications , Cardiovascular Diseases/mortality , Disease-Free Survival , Female , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Prospective Studies
13.
Nephrol Dial Transplant ; 22(12): 3631-7, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17611248

ABSTRACT

BACKGROUND: The introduction of sirolimus as an immunosuppressive drug for renal transplantation has lead to an increase of unexplained interstitial pneumonitis. METHODS: Out of a cohort of 115 patients receiving sirolimus for prophylaxis of renal and/or pancreas transplant rejection, 11 patients with interstitial pneumonitis were identified. Medical records and published case series were reviewed to identify risk factors associated with the occurrence of pneumonitis. RESULTS: Eleven out of 80 patients (14%) with late switch to sirolimus developed pneumonitis, in contrast to none of the 35 patients with de novo use of sirolimus. The mean sirolimus trough level at presentation was 16.7 mug/l (range: 6.2-38.7 mug/l). Glomerular filtration rate (GFR) was significantly lower in patients with pneumonitis compared to controls (mean 21.3 +/- 3.9 ml/min vs 38.65 +/- 2.14 ml/min P = 0.002). Two patients needed haemodialysis shortly before pneumonitis was diagnosed. In a multivariate analysis only serum creatinine and GFR were independent predictors for pneumonitis. Sirolimus was discontinuated in five patients and the dose reduced in the other patients. Pneumonitis resolved within 14-28 days in all patients. One patient who had continued low-dose sirolimus treatment relapsed after 5 months, the other five patients had no relapse over a period of 15-48 months. Pooled analysis of our data and other published case series showed that the frequency of pneumonitis in patients with de novo use of sirolimus is significantly lower than in patients with late switch [5/133 (4%) vs 46/326 (14%) patients, P = 0.0024]. CONCLUSIONS: Late switch to sirolimus and impaired renal function are risk factors for pneumonitis. A sirolimus blood trough level above 12 mug/l may increase the risk, but pneumonitis may also occur at blood trough levels as low as 6 mug/l. Since pneumonitis may recur during low-dose sirolimus treatment, discontinuation of sirolimus appears to be the safest treatment option.


Subject(s)
Immunosuppressive Agents/adverse effects , Pneumonia/chemically induced , Sirolimus/adverse effects , Adult , Aged , Female , Humans , Male , Middle Aged , Pneumonia/diagnosis , Risk Factors
14.
BMC Med ; 5: 1, 2007 Jan 01.
Article in English | MEDLINE | ID: mdl-17198546

ABSTRACT

BACKGROUND: The increased sympathetic nervous activity in patients with obstructive sleep apnea (OSA) is largely responsible for the high prevalence of arterial hypertension, and it is suggested to adversely affect triglyceride and high-density lipoprotein (HDL) cholesterol levels in these patients. The functionally relevant polymorphisms of the beta2-adrenergic receptor (Arg-47Cys/Arg16Gly and Gln27Glu) have been shown to exert modifying effects on these risk factors in previous studies, but results are inconsistent. METHODS: We investigated a group of 429 patients (55 +/- 10.7 years; 361 men, 68 women) with moderate to severe obstructive sleep apnea (apnea/hypopnea index (AHI) 29.1 +/- 23.1/h) and, on average, a high cardiovascular risk profile (body mass index 31.1 +/- 5.6, with hypertension in 60.1%, dyslipidemia in 49.2%, and diabetes in 17.2% of patients). We typed the beta2-adrenergic receptor polymorphisms and investigated the five most frequent haplotypes for their modifying effects on OSA-induced changes in blood pressure, heart rate, and lipid levels. The prevalence of cardiovascular risk factors and coronary heart disease (n = 55, 12.8%) and survived myocardial infarction (n = 27, 6.3%) were compared between the genotypes and haplotypes. RESULTS: Multivariate linear/logistic regressions revealed a significant and independent (from BMI, age, sex, presence of diabetes, use of antidiabetic, lipid-lowering, and antihypertensive medication) influence of AHI on daytime systolic and diastolic blood pressure, heart rate, prevalence of hypertension, and triglyceride and HDL levels. The beta2-adrenergic receptor genotypes and haplotypes showed no modifying effects on these relationships or on the prevalence of dyslipidemia, diabetes, and coronary heart disease, yet, for all three polymorphisms, heterozygous carriers had a significantly lower relative risk for myocardial infarction (Arg-47Cys: n = 195, odds ratio (OR) = 0.32, P = 0.012; Arg16Gly: n = 197, OR = 0.39, P = 0.031; Gln27Glu: OR = 0.37, P = 0.023). Carriers of the most frequent haplotype (n = 113) (haplotype 1; heterozygous for all three polymorphisms) showed a five-fold lower prevalence of survived myocardial infarction (OR = 0.21, P = 0.023). CONCLUSION: Our study showed no significant modifying effect of the functionally relevant beta2-adrenergic receptor polymorphisms on OSA-induced blood pressure, heart rate, or lipid changes. Nevertheless, heterozygosity of these polymorphisms is associated with a lower prevalence of survived myocardial infarction in this group with, on average, a high cardiovascular risk profile.


Subject(s)
Myocardial Infarction/complications , Myocardial Infarction/genetics , Polymorphism, Genetic , Receptors, Adrenergic, beta-2/genetics , Sleep Apnea, Obstructive/complications , Sleep Apnea, Obstructive/genetics , Aged , Blood Pressure , Cohort Studies , Female , Genotype , Humans , Male , Middle Aged , Multivariate Analysis , Myocardial Infarction/diagnosis , Risk Factors , Sleep Apnea, Obstructive/diagnosis
15.
Herz ; 31(4): 294-302, 2006 Jun.
Article in German | MEDLINE | ID: mdl-16810469

ABSTRACT

The pathophysiology of primary hypertension is still unresolved and appears more complex than ever. It is beyond the scope of this article to review all new scientific developments in this field. On clinical grounds, hypertension is divided into primary and secondary forms. Here, the authors discuss the pathophysiology of hypertension associated with three common disease entities showing a large overlap with primary hypertension: chronic kidney disease (CKD), obstructive sleep apnea (OSA), and hyperaldosteronism. Especially in CKD and OSA, the activation of the sympathetic nervous system plays a crucial role. It is the authors' belief that hypertension due to these three diseases is more common than previously appreciated and may account for about 20% of the hypertensive population. The knowledge of the underlying pathophysiology allows early diagnosis and guides optimal treatment of these hypertensive patients.


Subject(s)
Hyperaldosteronism/complications , Hypertension/etiology , Hypertension/physiopathology , Kidney Diseases/complications , Sleep Apnea, Obstructive/complications , Sympathetic Nervous System/physiopathology , Adipocytes/cytology , Animals , Body Mass Index , Cells, Cultured , Chronic Disease , Continuous Positive Airway Pressure , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/physiopathology , Endothelium, Vascular/physiopathology , Germany/epidemiology , Glomerular Filtration Rate , Humans , Hyperaldosteronism/epidemiology , Hyperaldosteronism/physiopathology , Hypertension/classification , Hypertension/therapy , Hypertension, Renal/etiology , Incidence , Kidney Diseases/epidemiology , Kidney Diseases/physiopathology , Metabolic Syndrome/complications , Overweight , Prevalence , Randomized Controlled Trials as Topic , Renal Insufficiency/complications , Renal Insufficiency/physiopathology , Renin-Angiotensin System/physiology , Risk Factors , Sleep Apnea, Obstructive/epidemiology , Sleep Apnea, Obstructive/physiopathology , Sleep Apnea, Obstructive/therapy , Time Factors
16.
Clin Sci (Lond) ; 110(1): 117-23, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16122377

ABSTRACT

OSA (obstructive sleep apnoea) stimulates sympathetic nervous activity and elevates resting HR (heart rate) and BP (blood pressure). In the present study in a cohort of 309 untreated OSA patients, the resting HR and BP during the daytime were correlated with AHI (apnoea/hypopnea index) and compared with patients with R389R (n = 162), R389G (n = 125) and G389G (n = 22) genotypes of the beta1-adrenoreceptor R389G polymorphism. We analysed the impact of the genotype on the decline of HR and BP in a subgroup of 148 patients (R389R, n = 86; R389G, n = 54; G389G, n = 8) during a 6-month follow-up period under CPAP (continuous positive airway pressure) therapy during which cardiovascular medication remained unchanged. In untreated OSA patients, we found an independent relationship between AHI and resting HR (beta = 0.096, P < 0.001), systolic BP (beta = 0.09, P = 0.021) and diastolic BP (beta = 0.059, P = 0.016). The resting HR/BP, however, did not differ among carriers with the R389R, R389G and G389G genotypes. CPAP therapy significantly reduced HR [-2.5 (-1.1 to -4.0) beats/min; values are mean difference (95% confidence intervals)] and diastolic BP [-3.2 (-1.5 to -5.0) mmHg]. The decline in HR was more significantly pronounced in the R389R group compared with the Gly(389) carriers [-4.1 (-2.3 to -5.9) beats/min (P < 0.001) compared with -0.2 (2.1 to -2.6) beats/min (P = 0.854) respectively; Student's t test between groups, P = 0.008]. Diastolic BP was decreased significantly (P < 0.001) only in Gly389 carriers (R389G or G389G) compared with R389R carriers [-5.0 (-2.3 to -7.6) mmHg compared with -2.0 (0.4 to -4.3) mmHg respectively]. ANOVA revealed a significant difference (P = 0.023) in HR reduction between the three genotypes [-4.1 (+/-8.4) beats/min for R389R, -0.5 (+/-9.3) beats/min for R389G and +1.9 (+/-7.2) beats/min for G389G]. In conclusion, although the R389G polymorphism of the beta1-adrenoceptor gene did not influence resting HR or BP in untreated OSA patients, it may modify the beneficial effects of CPAP therapy on these parameters.


Subject(s)
Blood Pressure/genetics , Heart Rate/genetics , Polymorphism, Genetic , Receptors, Adrenergic, beta-1/genetics , Sleep Apnea, Obstructive/genetics , Adult , Aged , Continuous Positive Airway Pressure , Female , Follow-Up Studies , Genotype , Humans , Male , Middle Aged , Polysomnography , Sleep Apnea, Obstructive/physiopathology , Sleep Apnea, Obstructive/therapy
17.
Med Klin (Munich) ; 101(11): 880-5, 2006 Nov 15.
Article in German | MEDLINE | ID: mdl-17235474

ABSTRACT

Obstructive sleep apnea and arterial hypertension are frequent diseases, but they are also often overlooked. There is a causal relationship of sleep apnea and hypertension. Undiagnosed sleep apnea is probably the most important reason for "essential" hypertension. It is important to identify these patients. All hypertensive patients should be asked for snoring, breathing arrest and daytime sleepiness, neck circumference should be measured, and an ambulant sleep apnea monitoring should be performed, if necessary. Especially patients with refractory hypertension or non-dippers should be screened for sleep apnea and patients with sleep apnea should be examined for arterial hypertension. Continuous positive airway pressure (CPAP) can effectively lower blood pressure in the hypertensive sleep apnea patient. This is especially true for the obstructive sleep apnea patient with refractory hypertension. CPAP therapy is probably the best therapy for sleep apnea-induced nocturnal blood pressure rises.


Subject(s)
Continuous Positive Airway Pressure , Hypertension/therapy , Sleep Apnea, Central/therapy , Sleep Apnea, Obstructive/therapy , Diagnosis, Differential , Heart Failure/etiology , Heart Failure/therapy , Humans , Hypertension/etiology , Mass Screening , Polysomnography , Sleep Apnea, Central/complications , Sleep Apnea, Central/diagnosis , Sleep Apnea, Obstructive/complications , Sleep Apnea, Obstructive/diagnosis
18.
BMC Gastroenterol ; 5: 24, 2005 Jul 18.
Article in English | MEDLINE | ID: mdl-16026609

ABSTRACT

BACKGROUND: Eosinophilic gastrointestinal disorders are an emerging disease entity characterized by eosinophilic infiltration of the intestinal wall. Oral steroids can be still considered as first line treatment. Unfortunately relapses are quite common. Usually long term low-dose prednisone or immunosuppressive therapy is required, which is especially problematic in young patients. Thus a reliable steroid sparing agent with low side effects suitable for long term use is needed. There are strong hints to a similar pathophysiology of eosinophilic gastrointestinal disorders to that of asthma. Indeed leukotriene D4 plays an important role in the recruitment of eosinophils into the intestinal tissue causing damage. This patho-mechanism provides the rationale for the treatment with a leukotriene D4 receptor antagonist. Recently there have been first reports about successful short term use of Montelukast in eosinophilic gastrointestinal disorders. CASE PRESENTATION: We report the case of a 17 year old girl with a long history of severe abdominal complaints leading to several hospitalizations in the past. Mimicking the picture of an intestinal tuberculosis she received an anti mycobacterial treatment without any success. Marked eosinophilia in blood, ascites and tissue samples of the intestinal tract finally lead to the diagnosis eosinophilic gastroenteritis. Tapering off prednisone caused another severe episode of abdominal pain. At that point leukotriene antagonist Montelukast was started at a dose of 10 mg once daily. Steroids could be tapered off completely within six weeks. The patient has been free of symptoms for over two years by now. Routine examinations, blood tests and endoscopy have rendered regular results. So far no side effects were noted. CONCLUSION: Here report about successful long term remission of eosinophilic gastroenteritis under Montelukast. Further randomized control trials are required to asses the full benefits of Montelukast therapy in the whole spectrum of eosinophilic gastrointestinal disorders.


Subject(s)
Acetates/therapeutic use , Eosinophilia/drug therapy , Gastroenteritis/drug therapy , Leukotriene Antagonists/therapeutic use , Quinolines/therapeutic use , Adolescent , Cyclopropanes , Female , Humans , Remission Induction , Sulfides
19.
Am J Hypertens ; 17(12 Pt 1): 1081-7, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15607612

ABSTRACT

BACKGROUND: There is increasing evidence that obstructive sleep apnea is an independent risk factor for arterial hypertension. Previous studies on the antihypertensive effects of positive airway pressure therapy on daytime blood pressure (BP) revealed inconsistent results. METHODS: The relations between the apnea/hypopnea index (AHI) and BP or heart rate (HR) were investigated in a cohort of 540 consecutive patients (age, 55.4 +/-11.1 years) with moderate or severe obstructive sleep apnea (OSA). The mean AHI was 28.2 +/- 22.0 events/h before OSA therapy. A group of 196 patients in whom antihypertensive medication was kept unchanged was followed for 6 months during bilevel or continuous positive airway pressure (Bi-/CPAP) therapy. RESULTS: Significant associations were found between AHI and systolic BP (beta = 0.078, P = .014), diastolic BP (beta = 0.056, P = .003), HR (beta = 0.096, P < .001), and the prevalence of arterial hypertension (odds ratio = 0.015, P = .003), independent of age, body mass index, and gender. During the follow-up period with effective Bi-/CPAP therapy, the mean daytime systolic BP decreased from 130.7 +/- 15.5 mm Hg to 128.6 +/- 15.9 mm Hg (P = .051), diastolic BP from 80.2 +/- 9.3 mm Hg to 77.5 +/- 9.5 mm Hg (P = .001), and HR from 77.7 +/- 8.8 to 75.7 +/- 8.1 beats/min (P = .001). Multiple linear regression analysis revealed that the absence of antihypertensive drugs and the level of the initial BP are significant and independent predictors for the lowering effect of Bi-/CPAP therapy on systolic and diastolic BP. CONCLUSIONS: This study confirms an independent relationship between the severity of OSA and BP/HR. Absence of BP-lowering medication and BP values before treatment are independent predictors for the reduction of BP with Bi-/CPAP therapy.


Subject(s)
Airway Resistance/drug effects , Antihypertensive Agents/pharmacology , Blood Pressure/drug effects , Hypertension/drug therapy , Sleep Apnea, Obstructive/physiopathology , Sleep Apnea, Obstructive/therapy , Adult , Aged , Antihypertensive Agents/therapeutic use , Continuous Positive Airway Pressure , Female , Follow-Up Studies , Germany/epidemiology , Heart Rate/drug effects , Humans , Hypertension/epidemiology , Hypertension/physiopathology , Linear Models , Male , Middle Aged , Multivariate Analysis , Myocardial Contraction/drug effects , Polysomnography , Predictive Value of Tests , Prevalence , Risk Factors , Severity of Illness Index , Sleep Apnea, Obstructive/epidemiology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...